Department of Pediatrics, Pediatric Diabetology Unit, Diabetes Research Institute, IRCCS Ospedale San Raffaele, Milan, Italy.
Department of Pediatrics, University of Campania Luigi Vanvitelli, Naples, Italy.
Eur J Endocrinol. 2021 Apr;184(4):575-585. doi: 10.1530/EJE-20-1030.
Transient neonatal diabetes mellitus (TNDM) is caused by activating mutations in ABCC8 and KCNJ11 genes (KATP/TNDM) or by chromosome 6q24 abnormalities (6q24/TNDM). We wanted to assess whether these different genetic aetiologies result in distinct clinical features.
Retrospective analysis of the Italian data set of patients with TNDM.
Clinical features and treatment of 22 KATP/TNDM patients and 12 6q24/TNDM patients were compared.
Fourteen KATP/TNDM probands had a carrier parent with abnormal glucose values, four patients with 6q24 showed macroglossia and/or umbilical hernia. Median age at diabetes onset and birth weight were lower in patients with 6q24 (1 week; -2.27 SD) than those with KATP mutations (4.0 weeks; -1.04 SD) (P = 0.009 and P = 0.007, respectively). Median time to remission was longer in KATP/TNDM than 6q24/TNDM (21.5 weeks vs 12 weeks) (P = 0.002). Two KATP/TNDM patients entered diabetes remission without pharmacological therapy. A proband with the ABCC8/L225P variant previously associated with permanent neonatal diabetes entered 7-year long remission after 1 year of sulfonylurea therapy. Seven diabetic individuals with KATP mutations were successfully treated with sulfonylurea monotherapy; four cases with relapsing 6q24/TNDM were treated with insulin, metformin or combination therapy.
If TNDM is suspected, KATP genes should be analyzed first with the exception of patients with macroglossia and/or umbilical hernia. Remission of diabetes without pharmacological therapy should not preclude genetic analysis. Early treatment with sulfonylurea may induce long-lasting remission of diabetes in patients with KATP mutations associated with PNDM. Adult patients carrying KATP/TNDM mutations respond favourably to sulfonylurea monotherapy.
瞬态新生儿糖尿病(TNDM)是由 ABCC8 和 KCNJ11 基因(KATP/TNDM)的激活突变或 6 号染色体 6q24 异常(6q24/TNDM)引起的。我们希望评估这些不同的遗传病因是否导致不同的临床特征。
对意大利 TNDM 患者数据集进行回顾性分析。
比较 22 例 KATP/TNDM 患者和 12 例 6q24/TNDM 患者的临床特征和治疗方法。
14 例 KATP/TNDM 先证者的父母一方存在血糖值异常,4 例 6q24 患者存在巨舌症和/或脐疝。6q24 组患者的糖尿病发病年龄和出生体重中位数(1 周;-2.27 SD)均低于 KATP 突变组(4.0 周;-1.04 SD)(P = 0.009 和 P = 0.007)。KATP/TNDM 组的缓解中位时间长于 6q24/TNDM 组(21.5 周 vs 12 周)(P = 0.002)。2 例 KATP/TNDM 患者无需药物治疗即进入糖尿病缓解期。1 例携带 ABCC8/L225P 变异的先证者曾被诊断为新生儿糖尿病,在接受磺脲类药物治疗 1 年后进入长达 7 年的缓解期。7 例 KATP 基因突变的糖尿病患者成功接受磺脲类药物单药治疗;4 例复发性 6q24/TNDM 患者接受胰岛素、二甲双胍或联合治疗。
如果怀疑为 TNDM,应首先分析 KATP 基因,除非患者存在巨舌症和/或脐疝。无需药物治疗即可缓解糖尿病不应排除基因分析。早期使用磺脲类药物可能会诱导 KATP 基因突变相关的 PNDM 患者的糖尿病长期缓解。携带 KATP/TNDM 突变的成年患者对磺脲类药物单药治疗反应良好。